Treatment for more Australians living with myeloma now available through Pharmaceutical Benefits Scheme (PBS)
- Advocacy and policy
- Media releases
- Myeloma
Tag: Advocacy and policy
PBAC reconsidered plitidepsin for myeloma 
The Pharmaceutical Benefits Advisory Committee (PBAC) considered four blood cancer treatments at its March 2020 meeting including a drug for myeloma – plitidepsin (Aplidin®).
- Advocacy and policy
- Myeloma
- Treatments and side-effects
Number of Australians living with blood cancer to more than double
- Advocacy and policy
- Media releases
Government’s commitment to blood cancer
The Leukaemia Foundation welcomes the commitment from the Federal Health Minister Greg Hunt to establish a Blood Cancer Taskforce and Action Plan.
- Advocacy and policy
- Media releases
National blood cancer taskforce meets
- Advocacy and policy
- Media releases
Leukaemia Foundation supports latest Pharmaceutical Benefits Scheme (PBS) listings for blood cancer patients
- Advocacy and policy
- Media releases
New national report reveals impact of blood cancer
- Advocacy and policy
- Media releases
Leukaemia Foundation supports Health Minister in PBS announcement for dasatinib
- Acute lymphoblastic leukaemia
- Advocacy and policy
- Media releases
Leukaemia Foundation supports Labor’s $20 million blood cancer Right to Trial
- Advocacy and policy
- Clinical trials
- Media releases
Welcome commitment to reduce out-of-pocket cancer costs
- Advocacy and policy
- Media releases
- “Live life to the fullest”: Josh Gourlay opens up about returning to work and new beginnings after blood cancer
- Advocacy news – July 2024
- Talking Blood Cancer: Estate planning and medical directives
- Running for a Cause: Cal Gates’ Journey from Newcastle to Sydney on foot in one weekend
- World Blood Cancer Day 2024